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An association between human papillomavirus (HPV) and 
cervical cancer has been established. Two HPV-subtypes, 
16 and 18, contribute to most cervical cancer cases 
(Doorbar, Quint, Banks, et al., 2012; Walboomers, Jacobs, 
Manos, et al., 1999). These subtypes are also the cause of 
penile, vaginal, vulvar, oropharyngeal and anal cancers 
(Bonafide, Vanable, 2015; Backes, Kurman, Pimenta, et al., 
2009). Despite introduction of an HPV vaccine in 2006, 
average vaccination percentages remain low. Nationally, 
only 37.6% of female and 13.9% of male adolescents aged 
13-17 years received greater than or equal to 3 doses of the 
HPV vaccine (CDC, 2014).  
 
Both the bivalent (HPV2) and quadrivalent (HPV4) 
vaccines have received positive safety profile reviews with 
the most common complaint being pain at the injection site, 
which resolves shortly after injection (Denny, International 
Federation of Gynecology and Obstetrics, 2013). Safety of 
the HPV2 vaccine has been monitored largely by the 
PATRICIA trial (Lehtinen, Paavonen, Wheeler, et al., 2012) 
and the Costa Rica vaccine trial (Herrero, Hildesheim, 
Rodríguez, et al., 2008); the HPV4 vaccine has been 
assessed by the FUTURE I and FUTURE II trials 
(McCormack, 2014), all with results suggesting adequate 
vaccine safety (De Vincenzo, Conte, Ricci, et al., 2014). 
The efficacy of the HPV2 and HPV4 vaccines has also been 
assessed in trials. Both prevent 90-100% of new HPV 16 
and 18 infections and associated grade 2 or higher cervical 
intraepithelial neoplasia, which are potentially premalignant 
transformations, in women not already infected with HPV 
16 or 18 at the time of vaccination (Herrero, González, 
Markowitz, 2015). Antibodies have remained at consistently 
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high levels for nearly 10 years, indicating that the vaccines 
remain effective for long periods (McCormack, 2014; Naud, 
Roteli-Martins, De Carvalho, et al., 2014). Despite evidence 
that the HPV vaccine is safe, effective, and long lasting, 
vaccination percentages remain low (CDC, 2014).  
 
Safety, effectiveness, and duration of the vaccine, as well as 
uncertainty about when to return for subsequent doses, were 
commonly cited as reasons not to receive the vaccine 
(Krawczyk, Perez, King, et al., 2015; Moore, Crosby, 
Young, et al., 2010; Printz, 2013). Further, participants who 
did not intend to receive the HPV vaccine cited vaccine 
safety and low perceived need as their motivating reasons; 
those intending to receive the vaccine cited practical 
concerns, such as cost, as barriers to receiving vaccination 
(Gerend, Shepherd, Shepherd, 2013). One study consistent 
with the Information-Motivation-Behavioral Skills model 
suggested that well-informed individuals who were 
motivated to act on their knowledge of the HPV vaccine and 
possess the behavioral skills necessary to overcome the 
barriers of vaccination would complete the HPV vaccine 
series (Fisher, Fisher, Harman, 2003; Fisher, 2012). In 
alignment with the Health Belief Model, HPV vaccine 
acceptability was higher when people believed that the 
vaccine was effective, a physician recommended it, and 
HPV infection was likely (Becker, 1974; Brewer, Fazekas, 
2007).  
 
Though these generalized determinants of HPV vaccination 
have been helpful, a more in-depth analysis at the county-
level is needed in order to understand disparities in HPV 
vaccine uptake and to identify specific populations who are 
at risk for not receiving the vaccine. Within the state of 
Georgia, only 33.2% of female and 15.3% of male 
adolescents aged 13-17 years received greater than or equal 
to 3 doses of the HPV vaccine (CDC, 2014). This finding 
reveals that female vaccination in Georgia falls below the 
national average of 37.6%, and that male vaccination is 
slightly greater than the national average of 13.9% (CDC, 
2014). The impact of low vaccination rates is seen through 
health disparities related to the higher incidence of cervical 
cancer in southern states, including Georgia, compared to 
other states (Markowitz, Dunne, Saraiya, et al., 2007). 
Health disparities, particularly in rural areas of the state, 
may be explained by a combination of culture, economy, 
and geographical location (Thomas, DiClemente, Snell, 
2014). Furthermore, a lack of information about sexual and 
reproductive health in rural communities can lead to 
parental mistrust and further healthcare disparities (Thomas, 
Strickland, Diclemente, et al. 2013).  
 
The focus of the present study was on the South Central 
Health District (SCHD) of Georgia, a rural public health 
district comprised of 10 counties. The objective was to 
conduct a descriptive epidemiological study of HPV 
vaccination coverage among individuals in the SCHD to 
provide guidance for targeted vaccination campaigns aimed 
at adolescents residing in rural communities. This study 
examined the relationship between demographic and 





Information from the AEGIS.net, Inc. (AEGIS) and the 
Georgia Registry of Immunization Transactions and 
Services (GRITS) databases from 2007-2014 were utilized. 
AEGIS is an intergovernmental health information database 
that documents health records of clients who sought services 
provided by the SCHD county health departments. GRITS, 
a registry managed by the Georgia Department of Public 
Health, includes complete and current vaccination records 
from across the state. Clients who received at least one dose 
of HPV vaccine from a county health department in the 
SCHD during this time frame were identified from AEGIS. 
GRITS was then used to measure vaccine series completion 
of the SCHD clients in case vaccine doses were 
administered outside of the SCHD. The Augusta University 
Institutional Review Board approved this study. 
 
Data Variables  
By use of AEGIS and GRITS, this research examined age, 
race, sex, and insurance status as key independent variables 
of HPV vaccine uptake due to their acknowledged relevance 
(CDC, 2014) and their availability in the administrative 
databases. The following variables were evaluated: reported 
county of HPV vaccine administration in the SCHD 
(Bleckley/ Dodge/ Johnson/ Laurens/ Montgomery/ Pulaski/ 
Telfair/ Treutlen/ Wheeler/ Wilcox), age at first vaccination, 
race (Asian/Black/Native Hawaiian and Other Pacific 
Islander/Multiracial/American Indian and Alaska 
Native/Unknown/White), sex (male/female/unknown), and 
insurance status at the most recent visit to the SCHD 
(yes/no/unknown). Anyone who received at least one HPV 
vaccine dose in the SCHD was recorded and completion 




The data provided by AEGIS and GRITS were used to 
examine vaccine completion percentages, defined as 
receiving all three injections in the series, among SCHD 
clients over time and across counties. A chi-square test for 
independence analyzed the relationships between 
categorical variables when each category had at least 5 
values; otherwise; a Fisher’s exact test was employed. For 
the continuous variable, age at first vaccination, a t-test was 
utilized. Counts and percentages were displayed where 
appropriate. All analyses were conducted using Stata 





From 2007 to 2014, county health departments within the 
SCHD provided at least one dose of vaccine in the HPV 
series to 2,362 clients throughout the district. Overall, 945 
(40%) completed the entire HPV vaccine series. Table 1 
shows demographic and socioeconomic characteristics of 
clients who received at least one dose of HPV vaccine 
through a health department in the SCHD during this time 
period. Similar to statewide data, the proportion of females 
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who completed the HPV vaccine series was significantly 
greater than that for males (p < 0.001). Additionally, the 
distribution across counties was significantly different (p < 
0.001) in regard to completion status. In the SCHD data, 
race was a significant variable in regard to vaccine series 
completion (p=0.011) with a larger proportion of white 
clients completing the series compared to other racial 
groups. The presence or absence of insurance was not 




Table 1. Demographic and socioeconomic factors associated with completion of the HPV vaccine in the SCHD of 
Georgia (AEGIS, GRITS 2007-2014) 
Variable Series Incomplete (1417, 60%) 
Series Complete 
(945, 40%) p-value 
 Mean Std. Dev. Mean Std. Dev.  
Age at 1st Vaccination* 12.0 0.1 12.0 0.1 0.054 
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*All unknown or missing values for age were removed resulting in n=2339.  
 
Table 2. Number of HPV vaccine doses received by sex in the SCHD (AEGIS, GRITS 2007-2014) 






 Number Percentage Number Percentage 
1 191 52.3 663 33.3 
2 89 24.4 470 23.6 
3 85 23.3 858 43.1 
     
After excluding six subjects with unknown sex status, the 
association between sex and number of HPV vaccine doses 
received was determined (Table 2). Data relating to the 
number of subjects who did not receive HPV vaccination 
in the SCHD were not available. Among those who 
received at least one HPV vaccine dose in a SCHD county 
health department, females were more likely to receive all 
three HPV vaccine doses (43.1%) compared to males, who 
were more likely to receive only one (52.3%) (p-value < 
0.001). 
 
J Ga Public Health Assoc (2016), Vol. 5, No. 4 ISSN 2471-9773
http://www.gapha.org/jgpha/           326 Georgia Public Health Association
The number of individuals in the SCHD who received their 
1st vaccine dose from 2007-2014 is shown in Figure 1. 
Four individuals were excluded due to receiving their first 
vaccine dose outside of the evaluation period according to 
the GRITS database. A peak in initial HPV vaccinations 
was evident for 2010. However, initial HPV vaccinations 
in the study population declined in 2011 and remained low.  
 
Figure 1. Individuals in the South Central Health District who initiated the HPV vaccine series by year 
(AEGIS, GRITS 2007-2014)  
 
 
Figure 2 highlights the percentages of vaccine series 
completion by county among individuals who received at 
least one vaccine dose at a county health department in the 
SCHD from 2007-2014. In Johnson County, the county 
with the highest completion percentage, more than 50% of 
individuals who received an HPV vaccination completed 
the series. In contrast, in Montgomery County, fewer than 
20% of individuals who received at least one HPV 
vaccination at the SCHD completed the series. Overall, 
there was variety in HPV completion percentages across 
the counties in the SCHD. 
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Figure 2. Completion percentage among individuals who received at least one HPV vaccine dose 
through the SCHD by county (AEGIS, GRITS 2007-2014)  
 
 
Among individuals who completed the HPV vaccine series, 
the average times to completion across counties served by 
the SCHD were determined (Figure 3). Montgomery 
County, at 334 days, had the fastest average series 
completion time; Wilcox County, at 800 days, had the 
slowest. Thus, Montgomery County had the lowest 
completion percentages in the SCHD, but individuals in 
Montgomery County who completed the HPV vaccine 
series did so quickly. 
Figure 3. Average time to completion among individuals in the SCHD who completed the 
vaccine series by county (AEGIS, GRITS 2007-2014) 
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DISCUSSION 
 
In the SCHD, males were fully vaccinated at lower 
percentages than females. Additionally, in 2010, an increase 
in vaccine delivery was evident across the study population. 
This increase was followed by a decline in the years 
following. On average, the completion percentage in each 
county in this SCHD subpopulation appeared to be higher 
than the statewide measure, but was still low. The results for 
vaccine completion reflect race as a significant variable in 
the SCHD.   
 
Since rural residence is negatively associated with HPV 
vaccine initiation (Du, Camacho, McCall-Hosenfeld, et al., 
2015), this research is particularly relevant for rural health. 
In the present study, differences in HPV vaccination 
percentages among counties were revealed. Completion 
percentages and average time to completion varied within 
the SCHD, indicating the individualized needs for each 
county. Variation among counties is supported by another 
study evaluating HPV vaccination in Georgia, revealing the 
importance of a county-level approach to increasing HPV 
vaccination (Thomas, Strickland, DiClemente, et al., 2013). 
Moving forward, studies of HPV vaccination in rural areas 
may benefit from considering county-level differences in 
addition to larger population analyses to meet the needs of 
the various communities. Because each county has different 
healthcare access and delivery challenges, health 
departments should be encouraged to incorporate a data-
driven approach by planning and allocating resources based 
on the documented needs of their specific subpopulations. 
However, the most prominent barrier to this approach would 
likely be the access to and analysis and interpretation of data 
needed for this type of informed decision making.  
 
Although overall vaccination rates remain low, school-based 
programs have shown promise in increasing HPV vaccine 
uptake at the community level. HPV vaccine completion 
among 11-12 year-old adolescents exceeded 80% in some 
areas of the UK and in Australia where school-based 
programs provided the vaccine (Brabin, Roberts, Stretch, et 
al., 2008; Stretch, 2008; Reeve, De La Rue, Pashen, et al., 
2008; Watson, Shaw, Molchanoff, et al., 2009; Brotherton, 
Deeks, Campbell-Lloyd, et al., 2008). However there have 
been few studies of school-based programs in the United 
States, especially in rural settings. Greater insight into this 
field could be beneficial to the SCHD, as well as to Georgia 
as a whole.  Existing program evaluations showed that 
school-based interventions were likely to offer other 
vaccines in addition to that for HPV, provide additional 
information about vaccination programs, and administer the 
vaccinations during regular school hours (Stubbs, 2014; 
Won, Middleman, Auslander, et al., 2015; Caskey, Macario, 
Johnson, et al., 2013). Further, school-based programs were 
encouraged to seek long-term financial support, as 
sustainability of the program budget was a noted weakness 
(Daley, Kempe, Pyrzanowski, et al., 2014; Hayes, Entzel, 
Berger, et al., 2013). In one program evaluation, parents 
whose sons did not have regular doctor’s visits were more 
comfortable with their son receiving the HPV vaccine at a 
school, indicating a possible target population (Reiter, 
McRee, Pepper, et al., 2012). Another study assessing 
parental acceptance of HPV vaccination found that parental 
opinion on severity of illness and intent to vaccinate 
adolescents correlated with parental acceptance of school 
programs, indicating a need for parental education in regard 
to the importance of the HPV vaccine (Gargano, Weiss, 
Underwood, et al., 2015). Through further assessment of 
school-based programs, rural health districts could develop 
vaccine campaigns best suited to their target population.  
 
Strengths of this study included the fact that, to conduct a 
comprehensive edpidemiological assessement of this rural 
population, data were gathered from two sources, GRITS 
and AEGIS. By utilizing GRITS data, this research allowed 
inclusion of vaccine data from people who received 
additional HPV vaccine doses outside of the SCHD. 
Additionally, this study used a methodological approach to 
provide evidence-based recommendations for a 
predominately rural population in Georgia. The results led 
to a better understanding of the demographic and 
socioeconomic characteristics associated with HPV vaccine 
uptake in rural areas.  
 
Limitations included that the information gathered from the 
SCHD reflected only individuals who had received at least 
one HPV vaccine dose from one of the ten county health 
departments. Information regarding adolescents who 
received HPV vaccinations from private providers in this 
region or who received additional vaccinations without 
GRITS documentation was not examined. Furthermore, the 
residence of the SCHD clients may not have been within the 
county where they received the HPV vaccine. Additionally, 
variables assessed were limited to those available in AEGIS 
and GRITS, which excluded some behavioral, social, 
motivational, and attitudinal variables that would have been 
beneficial to evaluate.  
 
As a means of increasing vaccine compliance, future areas 
of research should focus on why parents or guardians of 
adolescents choose to vaccinate their children, especially in 
rural areas. Due to comparable findings at the local level, 
where overall vaccine uptake and completion was low, 
targeted interventions should be implemented with a focus 
on high-risk groups such as males. Furthermore, research 
could examine the effectiveness of school-based 
interventions that encourage an increase in HPV vaccine 
compliance in the general adolescent population across 
Georgia. Future research could also focus on healthcare 
provider training in how to address concerns about HPV 
vaccination. Since healthcare providers have great influence 
in rural areas, addressing their knowledge and apprehension 
in providing vaccine recommendations would be a way to 




By conducting a descriptive epidemiological study of HPV 
vaccination coverage in the SCHD, we identified 
demographic and socioeconomic characteristics of 
individuals who may benefit from additional intervention 
practices in order to increase uptake and completion of the 
HPV vaccine series. These individuals include males, non-
White clients, and individuals living in counties with low 
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percentages of HPV vaccine completion. Broad-scale 
interventions, such as school-based vaccination programs, 
may be an effective method to increase overall vaccine 
initiation and completion rates across various demographic 
and socioeconomic groups, and especially in rural 
communities.   
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